Johnson and Johnson’s experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency’s human medicines committee (CHMP) at its May meeting.
The vaccine, developed by J&J group Janssen, provides active immunisation to prevent Ebola virus disease (Zaire ebolavirus species) in individuals aged one year and older.
It consists of two components, Zabdeno (Ad26.ZEBOV), which is given first, and Mvabea (MVA-BN-Filo), given around eight weeks later.
Zabdeno and Mvabea received a positive opinion for marketing authorisations under exceptional circumstances ‘because the applicant was able to demonstrate that it is not possible to conduct a randomised controlled study that might generate comprehensive clinical data on the efficacy of the new Ebola vaccine even after authorisation’, the agency noted.
Elsewhere, the following medicines also took giant leap closer to EU approval:
By: Selina McKee
Source: Pharma Times
The European Commission (EC) has approved Novartis’ Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) for uncontrolled asthma. More specifically, the drug has been cleared as a maintenance treatment […]
As COVID-19 vaccines near final stages of testing, governments are also racing against each other, busy securing supply for their own countries even before key efficacy data readouts. After signing […]
Johnson & Johnson has been on a manufacturing deal spree as it nears human trials for its COVID-19 vaccine hopeful. On the same day it inked a $480 order from […]
